Long-Term Outcomes of Older Diabetic Patients After Percutaneous Coronary Stenting in the United States A Report From the National Cardiovascular Data Registry, 2004 to 2008 by Hillegass, William B. et al.
Journal of the American College of Cardiology Vol. 60, No. 22, 2012
© 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00CLINICAL RESEARCH Interventional Cardiology
Long-Term Outcomes of Older Diabetic Patients After
Percutaneous Coronary Stenting in the United States
A Report From the National Cardiovascular Data Registry, 2004 to 2008
William B. Hillegass, MD, MPH,* Manesh R. Patel, MD,† Lloyd W. Klein, MD,‡
Hitinder S. Gurm, MD,§ J. Matthew Brennan, MD,† Kevin J. Anstrom, PHD,† David Dai, PHD,†
Eric L. Eisenstein, DBA,† Eric D. Peterson, MD, MPH,† John C. Messenger, MD,
Pamela S. Douglas, MD†
Alabaster and Birmingham, Alabama; Durham, North Carolina; Chicago, Illinois; Ann Arbor, Michigan;
and Aurora, Colorado
Objectives The purpose of this study was to characterize long-term outcomes of percutaneous coronary intervention (PCI) in
elderly diabetic patients in routine practice.
Background Although drug-eluting stent (DES) implantation in diabetic patients is common practice, pivotal randomized trials
enrolled 2,500 diabetic patients, most of whom were 65 years of age.
Methods Data from 405,679 patients 65 years old (33% had diabetes mellitus, of whom 9.8% had insulin-treated dia-
betes mellitus [ITDM], and 23.3% had noninsulin-treated diabetes mellitus [NITDM]) undergoing PCI from 2004
to 2008 at 946 U.S. hospitals were linked with Medicare inpatient claims data.
Results Over 18.4 months median follow-up (25th to 75th percentile: 8.0 to 30.8 months), ITDM/NITDM were associated
with significantly increased adjusted hazards of death (hazard ratio [HR]: 1.91 [95% confidence interval (CI):
1.86 to 1.96], p  0.001/HR: 1.32 [95% CI: 1.29 to 1.35], p  0.001) and myocardial infarction (HR: 1.87
[95% CI: 1.79 to 1.95], p  0.001/HR: 1.29 [95% CI: 1.25 to 1.34], p  0.001) compared with nondiabetic pa-
tients. The adjusted hazard of undergoing additional revascularization procedures (HR: 1.14 [95% CI: 1.10 to
1.18, p  0.001/HR: 1.08 [95% CI: 1.05 to 1.10], p  0.001) and subsequent hospitalization for bleeding (HR:
1.40 [95% CI: 1.31 to 1.50], p  0.001/HR: 1.18 [95% CI: 1.13 to 1.24], p  0.001) were also significantly in-
creased. Compared with nondiabetic patients, there were similar excess risks associated with ITDM/NITDM in
patients selected for DES and BMS use; selection for use of DES was associated with reductions in death in
ITDM/NITDM and myocardial infarction in ITDM, but not NITDM. There were no significant interactions between
diabetes status and stent type for revascularization or bleeding.
Conclusions One-third of older patients undergoing PCI have diabetes. After adjustment for other comorbidities, diabetes, particu-
larly ITDM, remains independently and strongly associated with increased long-term adverse events after both DES
and BMS implantation. (J Am Coll Cardiol 2012;60:2280–9) © 2012 by the American College of Cardiology
Foundation
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December 4, 2012:2280–9 Stenting in Older Diabetic PatientsIn the balloon angioplasty and bare-metal stent (BMS) eras,
diabetes mellitus conferred increased risk of death, myocar-
dial infarction (MI), and subsequent revascularizations in
the 2- to 5-year follow-up after percutaneous coronary
intervention (PCI) (1–3). Diabetic patients over the age of
65 years had a particularly elevated risk of events, including 60%
increased mortality at 2 years (adjusted for baseline comorbidities),
compared with nondiabetic patients (1). Fewer than 800 diabetic
patients over the age of 65 were enrolled in pivotal randomized
controlled trials (RCTs) that examined drug-eluting stents (DES)
versus BMS (4,5). Furthermore, the 2- to 5-year outcomes of
treatment with DES or BMS in the contemporary DES era have
not been well characterized in a large cohort of older diabetic
patients in routine practice.
To measure longer-term “real-world” cardiovascular out-
comes in older diabetic patients undergoing PCI in the
DES era in the United States, data from the National
Cardiovascular Data Registry (NCDR) CathPCI Registry
were linked to the Center for Medicare and Medicaid Services
(CMS) national inpatient claims databases. This consecutive
population-based registry permits measuring: 1) the prevalence of
insulin-treated diabetes mellitus (ITDM) and noninsulin-treated
diabetes mellitus (NITDM) in older patients undergoing PCI;
2) the 2- to 4-year rates of death, MI, revascularization, and
hospitalization for bleeding after PCI with both DES and
BMS stratified by diabetes status in an all-comers older
population; and 3) the differences in baseline characteristics
and their relationship to outcomes of older diabetic patients
selected for DES and BMS implantation in the DES era in
routine clinical practice.
Methods
Study population. The CathPCI Registry, which is co-
ponsored by the American College of Cardiology (ACC)
nd the Society for Cardiovascular Angiography and Inter-
entions (SCAI), catalogs data on patient and hospital
haracteristics, clinical presentation, treatments, and in-
ospital outcomes for PCI procedures from 1,000 U.S.
sites. Data reported in NCDR-certified software undergoes
comprehensive data quality monitoring, including auditing.
The prospectively defined NCDR variables are available at:
http://www.ncdr.com.
This study included all Medicare-linked patients 65
years of age undergoing PCI who were enrolled in the
CathPCI Registry from January 1, 2004, to December 31,
2008 (6,7). Percutaneous coronary intervention procedure
codes were used to identify index procedures in the Medi-
care files, which were then linked to NCDR records using
indirect identifiers, as previously described (8). Patients
receiving both BMS and DES or missing diabetes status
were excluded from the analysis (Fig. 1). Patients were
categorized as: 1) nondiabetic; 2) ITDM; or 3) NITDM.
The Duke University Medical Center institutional review
board granted a waiver of the informed consent and autho-
rization for this study.Clinical endpoints. Four pri-
mary clinical endpoints were exam-
ined: 1) death; 2) MI; 3) additional
revascularization procedures; and 4)
follow-up bleeding requiring hos-
pitalization. Clinical endpoints
were defined post-discharge with
the Medicare claims file using the
primary International Classifica-
tion of Diseases, Ninth Revision,
Clinical Modification (ICD-9-
CM) diagnosis codes for the hos-
pital admission (listed in Online
Table 1). Only revascularizations
occurring after discharge from the
index hospital stay were included
as revascularization endpoints.
Statistical analysis. Baseline
characteristics for the overall
population were categorized by
stent type (i.e., DES vs. BMS)
and diabetes status (i.e., no dia-
betes, NITDM, and ITDM) and
summarized as counts and per-
centages for categorical variables
and means with standard devia-
tions for continuous variables.
Differences between groups were
compared using chi-square tests
for categorical variables and the
Kruskal-Wallis test for continu-
ous variables. Statistical signifi-
cance was defined as p 0.05, with
no correction for multiple compari-
sons. The SAS statistical software
version 9.2 (SAS Institute, Cary, North Carolina) was used for
analyses.
Estimates of cumulative incidence rates by diabetes cat-
egory and stent type for time-to-event clinical outcomes
were based upon Gray’s method (9). To estimate the
prognostic differences between diabetic patients and nondi-
abetic patients undergoing coronary stenting, Cox propor-
tional hazard models were used within strata of BMS and
DES for each of the 4 primary endpoints. All baseline
characteristics with statistically significant differences across
diabetes status groups were included as covariates to esti-
mate the adjusted hazard ratio (HR) of ITDM and
NITDM compared with nondiabetic patients. A Cox model
including stent type, diabetes status, and the interaction of
stent type by diabetes status was created to evaluate for
significant interaction between stent type and diabetes status
for the 4 outcomes.
To examine whether the differences observed in outcomes
(mortality, myocardial infarction, additional revasculariza-
tion, and subsequent hospitalization for bleeding) between
Abbreviations
and Acronyms
ACC  American College of
Cardiology
BMS  bare-metal stent(s)
CI  confidence interval
CMS  Centers for
Medicare and Medicaid
Services
CVA  cerebrovascular
accident
DES  drug-eluting stent(s)
HR  hazard ratio
ICD-9-CM  International
Classification of Diseases-
Ninth Revision-Clinical
Modification
IPW  inverse probability
weighted
ITDM  insulin-treated
diabetes mellitus
MI  myocardial infarction
NCDR  National
Cardiovascular Data
Registry
NITDM  non-insulin-
treated diabetes mellitus
PCI  percutaneous
coronary intervention
RCT  randomized
controlled trial
SCAI  Society for
Cardiovascular Angiography
and Interventionsolder diabetic patients treated with DES versus BMS could
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Stenting in Older Diabetic Patients December 4, 2012:2280–9be explained by the baseline patient and procedural
characteristics measured in the CathPCI Registry, 2
statistical methods were employed. First, an inverse
probability-weighted (IPW) Cox model was derived for
the entire patient cohort (n  405,679). In this model,
each patient’s contribution is inversely weighted by their
predicted probability of receiving a DES. The IPW
adjusted HRs were calculated according to the approach
of Cole and Hernan (10).
Second, a subcohort (n  200,302) matched on propen-
sity scores was derived. Three different propensity score
models were created, for: 1) nondiabetic patients (n 
134,752); 2) ITDM (n  19,876); and 3) NITDM (n 
45,674). Propensity scores represent the estimated prob-
bilities of patients receiving DES versus BMS stratified
y diabetes status, which was conditioned upon 102
bserved covariates (Online Table 2). Drug-eluting stent
nd BMS patients with similar propensity scores were
atched using the Greedy 5¡1 digit matching algorithm
(11). Within the propensity score-matched cohorts, es-
timates of adjusted HR for DES versus BMS were
Figure 1 Study Population
Flow diagram and study population showing development of the study cohort from the
American College of Cardiology; BMS  bare-metal stent; CMS  Centers for Medicare aobtained using Cox models. IResults
Study population. From 2004 through 2008, 672,617
patients 65 years of age underwent stent implantation,
and 447,419 (67.0%) were linked to Medicare longitudinal
records. After exclusions (Fig. 1), the study population
included 405,679 patients from 946 sites. Except being less
likely to have commercial insurance (3% vs. 15%), the
baseline characteristics of the Medicare-linked CathPCI
Registry patients were very similar to those that failed to
link in the probabilistic matching, as reported previously (8).
he median follow-up was 18.4 months (25th to 75th
ercentile: 8.0 to 30.8 months) with a mean follow-up of
0  13.8 months).
aseline patient and procedural characteristics. The
revalence of diabetes was approximately one-third of
edicare patients undergoing PCI. Of the linked cohort
ndergoing PCI, 94,537 (23.3%) had NITDM, 39,770
9.8%) had ITDM, and 271,372 (66.9%) were nondiabetic.
aseline characteristics of the 405,679 patients stratified by
iabetes status and implanted stent type are shown in the
able. Within this older cohort undergoing PCI, the
ected National Cardiovascular Data Registry (NCDR) population. ACC 
icaid Services; DES  drug-eluting stent; PCI  percutaneous coronary intervention.unsel
nd MedTDM (73.5  6.1 years) and NITDM (74.2  6.4 years)
0(
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(75.2  6.8 years). As compared with nondiabetic patients,
those with diabetes had higher baseline rates of important
comorbidities. In contrast to these differences in baseline
comorbidities, procedural characteristics were not markedly
dissimilar between diabetic patients and nondiabetic pa-
tients. Overall, 73.3% (297,269 patients) received DES.
The frequency of DES use was similar among diabetic and
nondiabetic patients, with 73.1% DES implantation in
ITDM, 74.2% in NITDM, and 73.0% DES in nondiabetic
patients. The frequency of pre-procedural aspirin and clopi-
dogrel treatment, glycoprotein IIb/IIIa therapy during PCI,
number of stents deployed, frequency of type C lesions, and
multivessel intervention were also similar between nondia-
betic patients and diabetic patients.
Patients selected for DES were slightly younger, more
likely to be female, and less likely to smoke than patients
treated with BMS. Patients receiving DES also had lower
rates of renal insufficiency, stroke, coronary artery bypass
graft surgery, peripheral vascular disease, and lung disease,
but were more likely to have previously undergone PCI,
compared with BMS patients. Patients presenting with
STEMI were less likely to receive DES (58.8%) compared
with patients without STEMI (75.3%) (Table 1).
Diabetes mellitus, stent type, and outcomes. The unad-
justed cumulative incidence curves of death, MI, additional
revascularization procedures, and hospitalization for bleed-
ing stratified by diabetes status and type of stent implanted
are shown in Figure 2A to 2D. Within strata of DES and
BMS, the graded adverse association observed between
ITDM, NITDM, and no diabetes with death, MI, addi-
tional revascularizations, and hospitalization for bleeding
are highly significant between ITDM, NITDM, and no
diabetes (p  0.0001 for all comparisons).
Mortality. Among older Medicare patients treated with
DES, mortality at 3-year follow-up was 23.7% with ITDM,
14.2% for NITDM, and 11.1% for nondiabetic patients
(p  0.001). For patients treated with BMS, mortality at
3-year follow-up was 31.6% for ITDM, 20.8% for
NITDM, and 17.6% for nondiabetic patients (p  0.001).
Adjusting for all baseline differences listed in Table 1, both
ITDM (HR: 1.91 [95% confidence interval [CI]: 1.86 to
1.96], p 0.001) and NITDM (HR: 1.32 [95% CI: 1.29 to
1.35], p  0.001) remain significantly associated with
higher adjusted hazards of death. This excess mortality
hazard associated with ITDM and NITDM was similar
regardless of implanted stent type. Among the 297,269
older patients selected for DES, ITDM (HR: 1.98 [95% CI:
1.91 to 2.04], p 0.001) and NITDM (HR: 1.34 [95% CI:
1.31 to 1.38, p  0.001) were associated with a significantly
increased adjusted risk of death compared with nondiabetic
patients. In the 108,410 older patients selected for BMS in
the DES era, ITDM (HR: 1.76 [95% CI: 1.67 to 1.85], p
0.001) and NITDM (HR: 1.26 [95% CI: 1.20 to 1.31], p
0.001) were also associated with a similar significantly
increased adjusted risk of death compared with nondiabeticpatients. A significant protective interaction was observed in
the association between the presence of both ITDM (p 
.001) and NITDM (p  0.001) and DES implantation on
adjusted hazard for mortality. The main effect of ITDM
and NITDM is an association with a higher adjusted hazard
for mortality compared with nondiabetic patients. Given the
presence of ITDM and NITDM, the interaction suggests
selection for DES is associated with some mitigation of this
increased mortality risk compared with selection for BMS.
Again, this protective interaction between diabetes and
selection for DES on mortality hazard may arise from
unmeasured confounders.
The higher absolute mortality risk observed among pa-
tients selected for BMS compared with DES was time
dependent (Fig. 3). After an initial period of 15 to 18
months of declining quarterly incidence of death for the
cohort, a plateau of near-constant quarterly incidence of
death is observed within all strata of diabetes and stent type.
The early (p  0.001) and background plateau (p  0.01)
absolute mortality rates are significantly higher for ITDM
than for NITDM patients, which are both higher than for
nondiabetic patients.
Myocardial infarction. Similar to mortality, older ITDM
(HR: 1.87 [95% CI: 1.79 to 1.95], p 0.001) and NITDM
HR: 1.29 [95% CI: 1.25 to 1.33], p  0.001) patients
undergoing PCI had a significantly higher adjusted hazard
of MI in follow-up compared with nondiabetic patients
regardless of stent type. Among the 297,269 DES treated
patients, ITDM (HR: 1.93 [95% CI: 1.84 to 2.03], p 
0.001) and NITDM (HR: 1.27 [95% CI: 1.22 to 1.32], p
0.001) were associated with a significantly increased risk of
MI. Among the 108,410 older patients selected for BMS,
ITDM (HR: 1.70 [95% CI: 1.57 to 1.85], p  0.001) and
NITDM (HR: 1.33 [95% CI: 1.25 to 1.42], p  0.001)
were also associated with a similar increased risk of MI
compared with nondiabetic patients. There was no signifi-
cant interaction between NITDM and stent type compared
with nondiabetic patients on the adjusted hazard of subse-
quent MI (p  0.72.); however, there was a significant
protective association between ITDM and DES placement
on the subsequent adjusted hazard of MI (p  0.001).
Additional revascularization procedures. Older ITDM
(HR: 1.14 [95% CI: 1.11 to 1.18, p  0.001) and NITDM
(HR: 1.08 [95% CI: 1.05 to 1.11], p  0.001) patients
undergoing PCI had higher adjusted hazard of subsequent
revascularization procedures with either PCI or coronary
artery bypass graft surgery than nondiabetic patients regard-
less of stent type implanted. After selection for DES
implantation, the additional revascularization rates observed
at 18 months of follow-up (a time point at which events
related to restenosis have typically become manifest) were
15.9% for ITDM, 14.5% for NITDM, and 12.8% for
nondiabetic patients (p 0.001). For DES-treated patients,
the adjusted hazard for additional revascularization proce-
dures in ITDM (adjusted HR: 1.14 [95% CI: 1.10 to 1.18],
p 0.001) and NITDM (adjusted HR: 1.07 [95% CI: 1.05
Baseline Patient and Procedural Characteristics for Entire Cohort*Table 1 Baseline Patient and Procedural Characteristics for Entire Cohort*
Characteristics
Overall
(n  405,679)
No DM
(n  271,372)
NITDM
(n  94,537)
ITDM
(n  39,770)
All Patients
(n  405,679)
DES
(n  198,014)
BMS
(n  73,358) p Value
DES
(n  70,132)
BMS
(n  24,365) p Value
DES
(n  29,083)
BMS
(n  10,687) p Value
Patient characteristics
Age, yrs 74.8 6.7 74.9 6.6 76.2 7.1 0.001 73.9 6.2 75.1 6.7 0.001 73.2 6.0 74.3 6.4 0.001
Male 233,355 (57.5%) 114,927 (58.0%) 43,522 (59.3%) 0.001 40,494 (57.7%) 14,468 (59.4%) 0.001 14,294 (49.1%) 5,650 (52.9%) 0.001
Current smoking 51,455 (12.7%) 26,024 (13.1%) 11,384 (15.5%) 0.001 7,490 (10.7%) 2,955 (12.1%) 0.001 2,518 (8.7%) 1,084 (10.1%) 0.001
CHF 55,723 (13.7%) 19,516 (9.9%) 9,068 (12.4%) 0.001 10,970 (15.6%) 4,699 (19.3%) 0.001 8,060 (27.7%) 3,410 (31.9%) 0.001
Dialysis renal failure 7,466 (1.8%) 1,684 (0.9%) 975 (1.3%) 0.001 1,313 (1.9%) 656 (2.7%) 0.001 1,902 (6.5%) 936 (8.8%) 0.001
PVD 61,455 (15.1%) 24,850 (12.5%) 10,780 (14.7%) 0.001 11,468 (16.3%) 4,567 (18.7%) 0.001 7,013 (24.1%) 2,777 (26.0%) 0.001
Stroke 64,820 (16.0%) 27,345 (13.8%) 11,521 (15.7%) 0.001 11,898 (17.0%) 4,760 (19.5%) 0.001 6,586 (22.6%) 2,710 (25.4%) 0.001
Chronic lung disease 77,449 (19.1%) 34,981 (17.7%) 15,027 (20.5%) 0.001 12,882 (18.4%) 5,085 (20.9%) 0.001 6,680 (23.0%) 2,794 (26.1%) 0.001
Prior PCI 108,242 (26.7%) 52,332 (26.4%) 15,379 (21.0%) 0.001 21,417 (30.5%) 6,096 (25.0%) 0.001 9,999 (34.4%) 3,019 (28.2%) 0.001
Prior CABG 89,797 (22.1%) 37,850 (19.1%) 15,275 (20.8%) 0.001 17,264 (24.6%) 6,650 (27.3%) 0.001 9,032 (31.1%) 3,726 (34.9%) 0.001
Prior MI 101,215 (24.9%) 45,413 (22.9%) 17,065 (23.3%) 0.071 18,980 (27.0%) 6,678 (27.4%) 0.276 9,449 (32.5%) 3,630 (34.0%) 0.005
Procedural characteristics
Elective 193,142 (47.6%) 98,348 (49.7%) 28,816 (39.3%) 0.001 36,817 (52.5%) 10,408 (42.7%) 0.001 14,422 (49.6%) 4,331 (40.5%) 0.001
Urgent 156,099 (38.5%) 74,646 (37.7%) 27,166 (37.0%) 0.002 27,218 (38.8%) 9,704 (39.8%) 0.004 12,576 (43.2%) 4,789 (44.8%) 0.005
Emergent 55,275 (13.6%) 24,646 (12.4%) 16,927 (23.1%) 0.001 6,043 (8.6%) 4,116 (16.9%) 0.001 2,034 (7.0%) 1,509 (14.1%) 0.001
Stable angina 63,298 (15.6%) 33,145 (16.7%) 8,781 (12.0%) 0.001 12,570 (17.9%) 3,115 (12.8%) 0.001 4,472 (15.4%) 1,215 (11.4%) 0.001
Unstable angina 135,083 (33.3%) 69,165 (34.9%) 19,778 (27.0%) 0.001 25,156 (35.9%) 7,108 (29.2%) 0.001 10,695 (36.8%) 3,181 (29.8%) 0.001
NSTEMI 71,635 (17.7%) 32,006 (16.2%) 14,826 (20.2%) 0.001 11,351 (16.2%) 5,088 (20.9%) 0.001 5,706 (19.6%) 2,658 (24.9%) 0.001
STEMI 49,857 (12.3%) 22,530 (11.4%) 15,608 (21.3%) 0.001 5,207 (7.4%) 3,668 (15.1%) 0.001 1,603 (5.5%) 1,241 (11.6%) 0.001
Multivessel PCI 59,646 (14.7%) 30,387 (15.3%) 7,890 (10.8%) 0.001 11,867 (16.9%) 2,932 (12.0%) 0.001 5,169 (17.8%) 1,401 (13.1%) 0.001
Stents per patient
1 253,854 (62.6%) 122,036 (61.6%) 48,990 (66.8%) 0.001 42,398 (60.4%) 16,196 (66.5%) 0.001 17,238 (59.3%) 6,996 (65.5%) 0.001
2 151,825 (37.4%) 75,978 (38.4%) 24,368 (33.2%) 0.001 27,774 (39.6%) 8,169 (33.5%) 0.001 11,845 (40.7%) 3,691 (34.5%) 0.001
ACC-AHA type C lesions 172,712 (42.6%) 82,863 (41.8%) 32,297 (44.0%) 0.001 29,464 (42.0%) 10,583 (43.4%) 0.001 12,657 (43.5%) 4,848 (45.4%) 0.001
Values are mean  SD or n (%). *The percentages shown are the frequency of the factor within all the patients (overall) compared with the frequency among drug-eluting stent (DES) and bare-metal stent (BMS) recipients within each strata of diabetes mellitus (DM).
ACC-AHA American College of Cardiology-American Heart Association; CABG coronary artery bypass graft surgery; CHF congestive heart failure; HTN hypertension; ITDM insulin-treated diabetes mellitus; MImyocardial infarction; NITDM noninsulin-treated
diabetes mellitus; NSTEMI  non–ST-segment elevation myocardial infarction; PCI  percutaneous coronary intervention; STEMI  ST-segment elevation myocardial infarction.
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December 4, 2012:2280–9 Stenting in Older Diabetic Patientsto 1.10], p  0.001) was higher compared with nondiabetic
atients. For BMS-treated patients, additional revascular-
zation rates at 18 months of follow-up were 15.5% for
TDM, 15.0% for NITDM, and 13.3% for nondiabetic
atients (p  0.001). The excess hazard of additional
revascularization associated with diabetes among those se-
lected for BMS with ITDM (adjusted HR: 1.14 [95% CI:
1.07 to 1.21]) and NITDM (adjusted HR: 1.08 [95% CI:
1.04 to 1.13]) were similar to diabetic patients selected for
Figure 3 Trend in Quarterly Incidence of
Death After Coronary Stent Placement
Trend in the quarterly unadjusted death rates after stent implantation by diabe-
tes status (insulin-treated diabetes mellitus [ITDM] or noninsulin-treated diabe-
tes mellitus [NITDM]), and stent type (gray lines indicate bare-metal stent
[BMS]; black lines indicate drug-eluting stent [DES]). (A) ITDM; (B) NITDM;
and (C) nondiabetic patients.Figure 2 Unadjusted Outcomes in Diabetic
Patients Receiving Coronary Stents
Outcomes according to (A) unadjusted death rates by diabetes mellitus (DM)
status (noninsulin-treated diabetes mellitus [NITDM] or insulin-treated diabetes
mellitus [ITDM]) and stent type (drug-eluting stent [DES] or bare-metal stent
[BMS]); (B) unadjusted myocardial infarction rates by diabetes status and
stent type; (C) unadjusted additional revascularization rates by diabetes status
and stent type; and (D) unadjusted hospitalization for bleeding rates by
diabetes status and stent type. Solid blue lines indicate no DM DES; dashed
blue lines indicate no DM BMS; solid red lines indicate NITDM DES; dashed red
lines indicate NITDM BMS; solid green lines indicate ITDM DES; dashed green
lines indicate ITDM BMS.
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(p 0.126), NITDM (p 0.763), and stent type compared
with nondiabetic patients on the adjusted hazard of addi-
tional revascularizations.
Subsequent hospitalization for bleeding. Subsequent
hospitalization for bleeding ranged from 3.1% among non-
diabetic patients receiving DES to 6.4% among ITDM
patients treated with BMS over 30 months of follow-up.
Patients with ITDM (adjusted HR: 1.40 [95% CI: 1.31 to
1.50], p  0.001) and NITDM (adjusted HR: 1.18 [95%
CI: 1.13 to 1.24], p  0.001) had significantly higher
hazard for subsequent hospitalization for bleeding after
PCI, compared with nondiabetic patients (Fig. 4).
Among the 297,269 older patients selected for DES,
ITDM (adjusted HR: 1.26 [95% CI: 0.99 to 1.62], p 
0.065) and NITDM (adjusted HR: 1.18 [95% CI: 1.00 to
1.42], p  0.052) had only a trend toward independent
association with a significantly increased risk of hospitaliza-
tion for bleeding compared with nondiabetic patients at
30-day follow-up. However, over 1 year of follow-up, the
typical minimum prescribed length of treatment with dual
antiplatelet therapy in those receiving DES, ITDM (ad-
justed HR: 1.30 [95% CI: 1.18 to 1.44] , p  0.001), and
NITDM (adjusted HR: 1.19 [95% CI: 1.11 to 1.28], p 
0.001) had significant increased association with subsequent
hospitalization for bleeding.
Similar findings were also observed among the 108,410
older patients treated with BMS. At 30 days, follow-up
corresponding to the typical minimum prescribed length of
treatment with dual antiplatelet therapy after BMS, ITDM
(adjusted HR: 1.17 [95% CI: 0.83 to 1.64], p  0.38), and
NITDM (adjusted HR: 1.07 [95% CI: 0.84 to 1.36], p 
Figure 4 Unadjusted and Adjusted Hazards of Death, MI, Addit
and Subsequent Hospitalization by Diabetes Status
Adjusted hazards with 95% confidence intervals for death, myocardial infarction (M
for all diabetic patients, insulin-treated diabetes mellitus (ITDM) patients, and non
betes mellitus (DM). Hazard ratio 1.0 indicates excess adjusted hazard of diabe0.59) were not independently associated with a significantly
increased risk of hospitalization for bleeding compared with
nondiabetic patients. Nevertheless, over 1 year of follow-up
in patients treated with BMS, ITDM (adjusted HR: 1.43
[95% CI: 1.23 to 1.66], p  0.001) and NITDM (adjusted
HR: 1.23 [95% CI: 1.10 to 1.37], p 0.001) had significant
independent associations with subsequent hospitalization
for bleeding. There were no significant interactions between
stent type and diabetes status and the adjusted hazard of
hospitalization for bleeding.
Comparison of DES and BMS outcomes in diabetic
patients in routine practice. The unadjusted rates for
subsequent death, MI, and hospitalization for bleeding are
significantly lower for both older diabetic patients and
nondiabetic patients selected for DES compared with BMS
in routine practice (Figs 2 and 5). This is also true for
additional revascularization procedures, except for the
ITDM subgroup.
However, as described previously, there are highly signif-
icant baseline differences in the patients selected for DES
versus BMS implantation in routine clinical practice regard-
less of diabetes status. As depicted in Figure 5, the adjusted
HRs remain significantly less for DES compared with BMS
for all strata of diabetes and for all 4 major endpoints with
IPW adjustment.
Propensity score matching of patients receiving DES and
BMS within strata of diabetes yields 2 groups with very
comparable baseline characteristics. In the propensity score-
matched subcohort (n  200,302), there were only small
residual measured baseline differences between the BMS
and DES recipients (Online Table 3). Except for subse-
quent hospitalization for bleeding in diabetic patients and
Revascularization,
itional revascularization (Revasc), and subsequent hospitalization for bleeding
-treated diabetes mellitus (NITDM) patients compared with patients with no dia-ional
I), add
insulin
tes.
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tion for DES remains associated with significantly lower
adjusted hazards of death, MI, and subsequent revascu-
larizations with propensity score matching.
Discussion
In this national cohort, diabetes was present in one-third of
older patients undergoing PCI in the DES era. Diabetic
patients had a substantially higher prevalence of important
baseline comorbidities. After adjustment for these known
baseline differences, the presence of ITDM was associated
with a doubling of subsequent relative hazards for death and
MI, a 17% relative increase in the hazard of subsequent
revascularization procedures, and a 39% relative increase in
the hazard of hospitalization for bleeding compared with
nondiabetic patients. Having NITDM also remained inde-
pendently associated with increased relative hazards of death
(32%), MI (28%), additional revascularization procedures
(8%), and hospitalization for bleeding (18%) in follow-up after
stent implantation compared with nondiabetic patients.
Consistent with prior studies in the balloon angioplasty
and BMS era as well as smaller, selected DES cohorts,
ITDM and NITDM still confer substantial independent
risk for adverse cardiovascular outcomes over 3- to 4-year
follow-up in older patients undergoing PCI in the DES era
(12–14). The relative magnitude of incremental risk con-
ferred by ITDM or NITDM remains similar, regardless of
DES or BMS implantation. The mechanisms for this
Figure 5 Unadjusted and Adjusted Hazard Ratios for Clinical Ev
(A) Unadjusted hazard ratio, (B) propensity score-matched hazard ratio, and (C) in
(CI) for clinical events comparing likelihood of death, myocardial infarction, revasc
diabetes subgroups. Hazard ratio 1.0 indicates that the outcomes associated w
BMS treatment.incremental risk of adverse cardiovascular events in olderdiabetic patients compared with nondiabetic patients, par-
ticularly for death and MI after PCI with both DES and
BMS, is likely multifactorial. Hypotheses include a greater
underlying burden of atherosclerosis, microvascular disease,
a prothrombotic state, more neointimal hyperplasia, greater
vascular inflammation, and/or further accumulation of
diabetes-related end-organ damage and comorbidities dur-
ing the 30- to 50-month follow-up period (12–18).
Medicare-aged diabetic patients undergoing PCI were
not observed to be substantially more likely (73.9%) than
nondiabetic patients (73.0%) to be treated with DES in
routine practice, which is a surprising observation given the
55% reduction in subsequent target vessel revascularization
with DES versus BMS in diabetic patients documented in
meta-analysis of the 22 randomized trials. Since less than
one-third of the 2,500 diabetic patients enrolled in the
RCTs were65 years old, the applicability of the RCT data
to unselected older diabetic patients encountered in routine
practice is not well characterized (4,5,13,14). Patients se-
lected for DES in routine practice had significantly lower
measured comorbidities than did patients treated with BMS
in this large cohort. Coupled with the substantially greater
baseline comorbidities of the diabetic patients, this explains
the similar utilization of DES in diabetic patients compared
with nondiabetic patients observed in consecutive patients
treated with PCI in routine practice.
Yet, not all of the observed difference in longer-term
outcomes in diabetic patients selected for DES compared
by Diabetes Status and Stent Type
probability weighted (IPW) adjusted hazard ratio with 95% confidence intervals
tion, and bleeding in drug-eluting stents (DES) versus bare-metal stents (BMS) by
ection for DES treatment are better than those associated with selection forents
verse
ulariza
ith selwith BMS can be explained by these known baseline
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ical presentation, left ventricular ejection fraction, number
of vessels diseased, cardiogenic shock, renal function, dial-
ysis, number of lesions and vessels treated, number of stents
implanted, chronic obstructive pulmonary disease, periph-
eral vascular disease, congestive heart failure history, prior
stroke, MI, coronary artery bypass graft surgery, and PCI
among 102 covariates does not fully explain the observed
differences in outcomes of death and MI between patients
selected for DES versus BMS in routine practice. For
example, among ITDM, the unadjusted relative hazard for
mortality is 32% (95% CI: 28% to 36%) lower with selection
for DES than BMS. Adjustment for measured baseline
differences reduces this to 18% (95% CI: 14% to 22%);
therefore, the 18% lower relative hazard of longer-term
mortality after selection for DES versus BMS implantation
is not explained by the available baseline and procedural
covariates in the CathPCI Registry.
Largely by design, the set of information collected in the
CathPCI Registry has been demonstrated to be highly
predictive of index hospitalization events and outcomes
(19). Despite the extensive set of covariates collected in the
CathPCI Registry, the residual differences in these impor-
tant longer-term outcomes with stent type suggest the need
for additional factors to explain these differences. Among
BMS-treated patients across all strata of diabetes, the higher
early incidence of death and MI suggests other unmeasured
(but important) factors are almost certainly being appropri-
ately considered in stent implantation decisions.
The lower subsequent hazard of additional revasculariza-
tion with selection for DES versus BMS may reflect the
efficacy of DES as demonstrated in the randomized trials.
Nevertheless, the difference in additional revascularization
rates observed in routine practice between DES and BMS
are considerably smaller than target vessel revascularization
rate differences in RCTs. This may be explained in part by
proof-of-concept RCTs necessarily excluding patients likely
to need subsequent procedures for additional lesions and
vessels. In addition to appropriate operator selection biases
based on the estimated likelihood of restenosis that we have
not measured, implantation of BMS in the DES era may be
a marker of patients less suitable for pursuing an invasive
strategy in the future. This notion is indirectly supported by
the observation of higher prior PCI rates among patients
receiving DES than BMS in this cohort.
A post-discharge follow-up major bleeding endpoint has
rarely been evaluated in previous observational comparisons
of DES and BMS treatment. The relatively small rates of
hospitalization for bleeding are reassuring from a patient
safety point of view. Given the longer duration of dual
antiplatelet therapy typically prescribed with DES versus
BMS treatment, one might expect a higher bleeding risk
with the prolonged dual antiplatelet therapy used with
DES, but we found that unadjusted bleeding rates were
lower with selection for DES than BMS in this cohort. This
almost certainly reflects operators considering additionalfactors in matching stent type to estimated patient bleeding
risk. After adjusting for all covariates, including contraindi-
cations to antiplatelet agents and anticoagulants, as well as
warfarin status in the propensity-matched cohort, the lower
hazard of bleeding in diabetic patients selected for DES
compared with BMS is largely explained. Conversely, dia-
betes status, particularly ITDM, is significantly associated
with both a higher unadjusted and adjusted risk of hospi-
talization for subsequent bleeding compared with nondia-
betic patients after stent placement.
Study strengths and limitations. The CathPCI Registry
represents 1,000 U.S. hospitals, thereby capturing a sig-
nificant portion of PCIs nationally. More than 50% of
patients undergoing PCI are 65 years of age or older. This
“all-comers” cohort includes older patients, many of whom
would have been excluded from the pivotal trials because of
age, comorbidities, or disease complexity such as additional
lesions likely requiring future procedures (13). The large size
of this cohort and length of follow-up perhaps allows
formulation of more accurate expectations of outcomes in
older diabetic patients treated with DES and BMS in the
DES era in our routine practice.
In contrast to the RCTs and meta-analyses, however,
these observational data have many inherent limitations for
comparing the efficacy of DES and BMS. Particularly based
on the early separation in the time-course of mortality and
MI rates after PCI with DES versus BMS, there are almost
certainly appropriate factors driving operator decisions be-
tween DES and BMS implantation that have not (or
cannot) be readily captured. These unmeasured confounders
might explain the differences in mortality, MI, and addi-
tional revascularization we have observed in routine practice.
Candidate factors for additional research are those that are
plausibly related to longer-term outcomes, including com-
peting noncardiovascular comorbidities, measures of throm-
botic tendency and inflammation, functional status, socio-
economic status, measures of adherence to medical therapy,
and patient frailty.
While this large observational registry does contain clinical
judgments as to contraindication to antiplatelet and anticoag-
ulant therapies as well as warfarin status, it is limited by the
absence of information on utilization and duration of dual
antiplatelet therapy for the bleeding endpoint.
Conclusions
In a large national consecutive cohort study of Medicare
beneficiaries undergoing PCI, 33% of older patients have
diabetes. A strong independent association was observed be-
tween diabetes (particularly ITDM) and increased cardiovas-
cular events in the 3 to 4 years after PCI, regardless of BMS or
DES implantation. These data quantitatively define the
expected 3- to 4-year outcomes of death, MI, additional
revascularization, and subsequent hospitalization for bleed-
ing in older diabetic patients undergoing either DES or
11
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